Interactive Professor

Improving Outcomes for Women with Type 2 Diabetes

Individualizing Evidence-Based Care

Meeting Slides

Suggested Readings

Sex Differences in Type 2 Diabetes: Focus on Disease Course and Outcomes

Arnetz L, et al. Diabetes Metab Syndr and Obes. 2014;7:409-420.

Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women

Baldani DP, et al. Int J of Endocrinol. 2015;2015:786362.

Parity and Diabetes Risk Among Hispanic Women From Colombia: Cross-sectional Evidence

Cure P, et al. Diabetol Metab Syndr. 2015;7:7.

Women Are Diagnosed With Type 2 Diabetes at Higher Body Mass Indices and Older Ages than Men: Korea National Health and Nutrition Examination Survey 2007-2010

Kwon SK. Diabetes Metab J. 2014;38(1):74-80 .

Impact of Sex on the Heart’s Metabolic and Functional Responses to Diabetic Therapies

Lyons MR, et al. Am J Physiol Heart Circ Physiol. 2013;305(11):H1584-H1591.

Diabetes Abrogates Sex Differences and Aggravates Cardiometabolic Risk in Postmenopausal Women

Mascarenhas-Melo F, et al. Cardiovasc Diabetol. 2013;12:61.

Sex Differences in the Excess Risk of Cardiovascular Diseases Associated With Type 2 Diabetes: Potential Explanations and Clinical Implications

Peters SAE, et al. Curr Cardiovasc Risk Rep. 2015;9(7):36.

Sex Differences in the Metabolic Syndrome: Implications for Cardiovascular Health in Women

Pradhan AD. Clin Chem. 2014;60(1):44-52.

Factors Associated With a Diabetes Diagnosis and Late Diabetes Diagnosis for Males and Females

Roche MM, Wang PP. J of Clin Transl Endocrinol. 2014;1(3):77-84.

Sex Differences in All-Cause and Cardiovascular Mortality, Hospitalization for Individuals With and Without Diabetes, and Patients With Diabetes Diagnosed Early and Late

Roche MM, Wang PP. Diabetes Care. 2013;36(9):2582-2590. 

Educational Materials for Patients, Family Members, and Caregivers

American Diabetes Association—Women—The Healthy Woman: A Complete Guide for All Ages—Type 2 Diabetes—Diabetes in Women

Interactive Presentation

Practice Pearls for Improving Outcomes for Women with T2DM

Eileen Egan, DNP, FNP-C, CDE

Improving Outcomes for Women With Type 2 Diabetes

Individualizing Evidence-Based Care

Relevant Resources

Incretin-Based Therapies for Type 2 Diabetes

Mechanism-Based Strategies to Achieve Patient-Centered Care

Insulin Replacement Therapy for Type 2 Diabetes

Patient-Centered Management of Hyperglycemia in Primary Care

Improving Outcomes in Type 2 Diabetes

Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens

A Focus on Bipolar Depression

Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes

Clinical Issues in Type 2 Diabetes

Discussions and Debates Around GLP-1 Receptor Agonists

Clinical Issues in Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Congenital and Acquired Lipodystrophy

Best Practices in Diagnosis and Management

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Clinical Updates in Type 2 Diabetes

An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Injecting New Ideas into Managing Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Multidimensional Issues in Type 2 Diabetes

Looking Beyond Hemoglobin A1c

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options

Pharmaceutical Economics and LDL-C Management

Implications for PCSK9 Inhibitors in Clinical Practice

Assimilating the Evidence in T2DM

Cardiovascular and Renal Outcomes With SGLT2 Inhibitors

Getting Low in Familial Hypercholesterolemia

Reducing LDL-C and a Lifetime of Cardiovascular Risk

Making the Call in Heart Failure

Multidimensional Outcomes With SGLT2 Inhibitors

Anemia in Chronic Kidney Disease

New Avenues to Improve Patient Outcomes